Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

Multiple Sclerosis

Volumn 10, Issue 4, 2004, Pages 434-441

  Wade, Derick T ^a,b   Makela, Petra ^a,b   Robson, Philip ^a,b   House, Heather ^a,b   Bateman, Cynthia ^a,b  

^a OXFORD CENTRE FOR ENABLEMENT   (United Kingdom)

^b The Research Centre   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoids; Delta 9 tetrahydrocannabinol; Multiple sclerosis; Patient selected outcome; Randomized controlled trial; Spasticity

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL; PLACEBO;

ADULT; AGED; ARTICLE; ATTENTION DEFICIT DISORDER; BLADDER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTOXICATION; DRUNKENNESS; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MOUTH ULCER; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; OUTCOMES RESEARCH; OUTPATIENT CARE; PAIN; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; SPASTICITY; SYMPTOMATOLOGY; TREMOR; VERTIGO; VISUAL ANALOG SCALE;

AEROSOLS; CANNABIDIOL; CANNABIS; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MOUTH MUCOSA; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PAIN; PAIN MEASUREMENT; PLANT EXTRACTS; TETRAHYDROCANNABINOL; TREMOR; URINARY BLADDER DISEASES;

EID: 4344582253     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1082oa     Document Type: Article

References (34)

1. Consroe P, Musty R, Rein J, Consroe P, Musty R, Rein J et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38: 44-48.
2. Killstein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-407.
3. Petro DJ, Ellenberger C. Treatment of human spasticity with delta-9-THC. J Clin Pharmacol 1981; 21: 413S-16S.
4. Ungerleider T, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50.
5. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW et al. Cannabinoids control spasticity and tremor in multiple sclerosis model. Nature 2000; 404: 84-87.
6. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995; 345: 579.
7. Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236: 120-22.
8. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13: 669-71.
9. Robson P. Cannabis as a medicine: time for the phoenix to rise? BMJ 1998; 316: 1034-35.
10. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000 60: 1303-14.
11. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-47.
12. McPartland J, Russo E. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Therap 2001; 1: 103-32.
13. Mechoulam R. Cannabinoid chemistry. In Mechoulam R ed. Marijuana - chemistry, pharmacology, metabolism and clinical effects. London: Academic Press, 1973: 1-99.
14. Whittle BA, Guy GW, Robson P. Prospects for new cannabis-based prescription medicines. J Cannabis Therap 2001; 1: 183-205.
15. Robson PJ, Guy GW. Clinical studies of cannabis-based medicines. In Guy GW, Whittle BA, Robson PJ eds. The medicinal uses of cannabis and cannabinoids. London: Pharmaceutical Press, 2004: 229-69.
16. Wade DT, Robson PJ, House H, Makela PM, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehab 2003; 17: 21-29.
17. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A on behalf of the UK MS research group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
18. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323:13-16.
19. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325: 1195-98.
20. Collin C, Wade DT, Davis S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud 1988; 10: 61-63.
21. Forlander DA, Bohannon RW. Rivermead Mobility Index: a brief review of research to date. Clin Rehab 1999; 13: 97-100.
22. Wade DT, Vergis E. The Short Orientation-Memory-Concentration test: a study of its reliability and validity. Clin Rehab 1999; 13: 164-70.
23. Vlaar AM, Wade DT. The Adult Memory & Information Processing Battery (AMIPB) test of information processing speed: a study of its reliability and feasibility in patients with multiple sclerosis. Clin Rehab 2003; 17: 386-93.
24. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9: 139-45.
25. Rossier P, Wade DT. The Guy's Neurological Disability Scale in patients with multiple sclerosis: a clinical evaluation of its reliability and validity. Clin Rehab 2002; 16: 75-95.
26. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561- 71.
27. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AF. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-23.
28. Gregson JM, Leathley M, Moore AP, Sharma AK, Smith TL, Watkins CL. Reliability of the Tone Assessment Scale and the Modified Ashworth scale as clinical tools for assessing post-stroke spasticity. Arch Phys Med Rehab 1999; 80: 1013-16.
29. Alusi SH, Worthington J, Glickman S, Findley LJ, Bain PG. Evaluation of three different ways of assessing tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 756-60.
30. Heller A, Wade DT, Wood VA, Sunderland A, Langton Hewer R, Ward E. Arm function after stroke: measurement and recovery over the first three months. J Neurol Neurosurg Psychiatry 1987; 50: 714-19.
31. Vahtera T, Haaranen M, Viramo-Koskela AL, Ruutiainen J. Pelvic floor rehabilitation is effective in multiple sclerosis. Clin Rehab 1997; 11: 211-21.
32. Lockwood K, Joyce B, Stolee P. Use of goal attainment scaling in measuring clinically important change in cognitive rehabilitation patients. J Clin Epidemiol 1997; 50: 581-88.
33. Donnelly C, Carswell A. Individualized outcome measures: a review of the literature. Can J Occup Ther 2002; 69: 84-94.
34. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical Importance of changes in chronic pain intensity measured on an 11-point numerical rating scale. Pain 2001; 94: 149-58.